The DAPA-HF [12], EMPEROR-Reduced [13], and EMPEROR-Preserved [14] trials have demonstrated significant clinical benefits with the addition of SGLT2 inhibitors to heart failure therapy, with no evidence supporting the discontinuation of MRAs in these patients. Here, SLC5A2 is linked to heart failure.